Meglumine antimoniate indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Meglumine antimoniate}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second E...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Indications and Usage== | |||
Treatment of: | |||
• visceral leishmaniasis | |||
• cutaneous leishmaniasis (except for L. aethiopica infections, which are unresponsive) | |||
• diffuse cutaneous leishmaniasis due to L. amazonensis | |||
• cutaneous and mucocutaneous leishmaniasis due to L. braziliensis. | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> |
Revision as of 03:39, 7 January 2014
Meglumine Antimoniate |
---|
GLUCANTIM® WHO Prescribing Information |
Description |
Indications and Usage |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Dosage and Administration |
How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
Treatment of:
• visceral leishmaniasis • cutaneous leishmaniasis (except for L. aethiopica infections, which are unresponsive) • diffuse cutaneous leishmaniasis due to L. amazonensis • cutaneous and mucocutaneous leishmaniasis due to L. braziliensis.
References
Adapted from the FDA Package Insert.